When loaded with anti-PDL1 for the treatment of melanoma, delivery via FCS nanocomplexes demonstrated the slowest tumor growth and longest survival in a mouse tumor model when compared to injected anti-PDL1. This evidence concerns the gene CD274 and neoplasm.